SLC25A45-Based GLP-1RA Response Diagnostic
A diagnostic test to identify patients who are likely to be resistant to GLP-1 receptor agonist (GLP-1RA) weight-loss drugs based on SLC25A45 genetic variants or expression levels.
Live prototype, embedded from its own deployment — interact right here.
Open full appConcept
A precision medicine diagnostic tool that screens for mutations or deficiencies in the SLC25A45 mitochondrial carrier. Because SLC25A45 is essential for carnitine biosynthesis and fatty acid oxidation, individuals with deficiencies in this carrier are resistant to the lipid-mobilizing effects of GLP-1RAs. This test would allow clinicians to identify 'non-responders' before prescribing expensive anti-obesity medications.
Why now
Research shows that SLC25A45 deficiency renders subjects resistant to adipose tissue loss induced by GLP-1RA [1]. Additionally, specific human mutations (such as R285C) are already associated with altered methylated amino acid levels in plasma [0], providing a concrete biological marker for screening.
AI assessment
A high-potential precision medicine diagnostic with a clear clinical wedge, though it relies on a relatively narrow set of mouse-model findings for its primary efficacy claim.
- Evidence strength 3/5
- The link between SLC25A45 and GLP-1RA resistance is strongly demonstrated in mice, but human clinical evidence is limited to a single mutation's effect on plasma markers.
- Market pull 5/5
- The massive adoption of GLP-1RAs creates an urgent need for clinicians to identify non-responders to avoid wasted cost and ineffective treatment.
- Novelty & moat 4/5
- Targeting a specific mitochondrial carrier for GLP-1RA response is a novel approach that creates a defensible biological moat.
- Feasibility 5/5
- Developing a genetic screen for a specific gene (SLC25A45) or a plasma assay for methylated amino acids is technically straightforward using existing NGS or LC-MS platforms.
- Wedge clarity 5/5
- The product has a sharp, single-purpose entry point: a companion diagnostic for GLP-1RA prescription.
- Simplicity / focus 5/5
- The idea is focused on one specific diagnostic test rather than an over-scoped metabolic platform.
Scored by AI against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity). A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Who benefits
- Obesity Clinic Patientsindividual
Avoids the frustration and cost of using a medication that is biologically ineffective for them due to a specific mitochondrial carrier deficiency.
- Pharmaceutical Companiescompany
Increases the reported efficacy rates of their GLP-1RA products by identifying and excluding non-responsive genetic subpopulations in clinical trials and real-world use.
- Novo Nordiskcompany
As a primary manufacturer of GLP-1RAs, they can improve drug efficacy rates by identifying non-responders via a companion diagnostic.
- Eli Lillycompany
Similar to Novo Nordisk, they benefit from reducing 'trial and error' in prescribing Zepbound/Mounjaro for obese patients.
- Mayo Clinicorganization
Clinicians can use the test to explain why certain patients fail to lose weight on GLP-1RAs and pivot to alternative metabolic interventions.
- Endocrinologistsindividual
Provides a biological explanation for why some patients fail to lose weight on GLP-1RAs, allowing for personalized treatment pivots.
Research it builds on
- SLC25A45 is required for mitochondrial uptake of methylated amino acids and de novo carnitine biosynthesisMarília M. Dias, Martin King, Engy Shokry et al. · 2025 · 10 citationsAll ideas from this paper →
- Mitochondrial control of fuel switching via carnitine biosynthesisChristopher Auger, Hiroshi Nishida, Bo Yuan et al. · 2026 · 7 citationsAll ideas from this paper →
Related ideas
- SLC25A45-Based Metabolic Biomarker Panel
A diagnostic blood test measuring SLC25A45 mutation status and methylated amino acid levels to predict patient response to GLP-1 receptor agonist weight-loss drugs. The panel identifies metabolic bottlenecks in carnitine biosynthesis that may hinder lipid mobilization.
same research - SLC25A45-Based GLP-1RA Responder Diagnostic
A companion diagnostic that uses SLC25A45 genetic variants and plasma trimethyllysine-to-carnitine ratios to predict whether a patient will lose adipose tissue on GLP-1 receptor agonist therapy (e.g., semaglutide, tirzepatide) before expensive treatment begins.
same research - Mutation-Risk Predictive Oncology Tool
A clinical decision support tool that predicts the window of time when a tumor is most likely to develop drug resistance based on its mutation rate.
- Intracellular 5-HT2AR Location-Bias Drug Screening Assay
A preclinical assay service that distinguishes between compounds activating cell-surface versus intracellular 5-HT2A receptors. This allows drug developers to isolate neuroplasticity-promoting effects from hallucinogenic activity, targeting a specific subcellular receptor pool.
- TEX44-Based Male Infertility Diagnostic Panel
A targeted genetic screening test for patients with asthenozoospermia to identify biallelic TEX44 variants and associated mitochondrial sheath defects. The panel aims to differentiate metabolic mitochondrial failures from other structural axonemal defects.
- Fusarium-Resistant Climbing Bean Seed Line
A seed variety of the Umubano climbing bean developed via backcross breeding to incorporate a dominant resistance gene against Fusarium wilt. The approach focuses on providing a high-yield alternative for contaminated soils while acknowledging the risk of fungal evolution.